From BioHealth Investor
Biotechnology
INNOVIVE PHARMACEUTL [IVPH.OB] +23.46%
XTL BIOPHARMACEUTICA [XTLB] +22.88%
STEMCELLS INC [STEM] +16.92%
MEMORY PHARMACEUTICA [MEMY] +16.73%
BIONOVO INC [BNVI.OB] +14.55%
Diagnostic Substances
RG GLBL LIFESTYLS [RGBL.OB] +47.39%
ORCHID CELLMARK INC [ORCH] +11.68%
IMMUCOR INC [BLUD] +7.40%
GENELABS TECH INC [GNLB] +5.59%
ICAGEN, INC. [ICGN] +5.56%
Drug Delivery
ALKERMES INC [ALKS] +3.74%
FLAMEL TECH SA ADR [FLML] +3.44%
BIOVAIL CORP [BVF] +1.89%
PETMED EXPRESS INC [PETS] +1.11%
DELCATH SYSTEMS INC [DCTH] +0.87%
Drug Manufacturers
NOVOGEN LTD ADS [NVGN] +11.21%
INSPIRE PHARMACEUT [ISPH] +8.86%
DEPOMED INC [DEPO] +6.29%
MARSHALL EDWARDS [MSHL] +5.96%
SIGA TECH INC [SIGA] +5.87%
Medical Appliances & Equipment
CHAD THERAPEUTICS [CTU] +9.00%
CYNOSURE, INC. [CYNO] +7.32%
THERMAGE, INC. [THRM] +6.43%
VISION SCIENCES IN [VSCI] +6.02%
BSD MEDICAL CORP [BSM] +5.64%
Medical Instruments & Supplies
MILESTONE SCIENTIFIC [MLSS.OB] +16.07%
ANGIODYNAMICS INC [ANGO] +15.57%
DTLL INC [DTLI.OB] +13.33%
OPHTHALMIC IMAGING SYS INC [OISI.OB] +9.09%
NEPHROS INC. [NEP] +8.61%
Medical Laboratories & Research
AASTROM BIOSCIENCE [ASTM] +12.10%
ARRAY BIOPHARMA IN [ARRY] +3.50%
ENZO BIOCHEM INC [ENZ] +2.95%
ERESEARCHTECHNOLOG [ERES] +2.86%
RADNET INC [RDNT.OB] +2.20%
http://www.biohealthinvestor.com/
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
